LLY

927.24

-5.67%↓

JNJ

239.19

-1.28%↓

ABBV

221.99

+0.16%↑

NVS

155.04

+0.27%↑

AZN

190.98

-0.45%↓

LLY

927.24

-5.67%↓

JNJ

239.19

-1.28%↓

ABBV

221.99

+0.16%↑

NVS

155.04

+0.27%↑

AZN

190.98

-0.45%↓

LLY

927.24

-5.67%↓

JNJ

239.19

-1.28%↓

ABBV

221.99

+0.16%↑

NVS

155.04

+0.27%↑

AZN

190.98

-0.45%↓

LLY

927.24

-5.67%↓

JNJ

239.19

-1.28%↓

ABBV

221.99

+0.16%↑

NVS

155.04

+0.27%↑

AZN

190.98

-0.45%↓

LLY

927.24

-5.67%↓

JNJ

239.19

-1.28%↓

ABBV

221.99

+0.16%↑

NVS

155.04

+0.27%↑

AZN

190.98

-0.45%↓

Home・Akciju saraksts・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	-0.05% downside

Ziņu noskaņojums

By Acuity

50%

150 / 351 Rangs Healthcare

Mirati Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 16. marts 21:37 UTC

Iegādes, apvienošanās, pārņemšana

Lensar and Alcon Agree to Terminate Merger

2026. g. 16. marts 19:06 UTC

Galvenie ziņu notikumi

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

2026. g. 16. marts 17:44 UTC

Iegādes, apvienošanās, pārņemšana

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

2026. g. 16. marts 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 16. marts 23:46 UTC

Tirgus saruna

Nikkei May Rise After Oil Prices Decline -- Market Talk

2026. g. 16. marts 23:37 UTC

Tirgus saruna

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026. g. 16. marts 23:05 UTC

Tirgus saruna

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

2026. g. 16. marts 21:56 UTC

Tirgus saruna

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

2026. g. 16. marts 21:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 16. marts 21:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

2026. g. 16. marts 20:59 UTC

Iegādes, apvienošanās, pārņemšana

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

2026. g. 16. marts 20:59 UTC

Iegādes, apvienošanās, pārņemšana

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

2026. g. 16. marts 20:59 UTC

Iegādes, apvienošanās, pārņemšana

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

2026. g. 16. marts 20:57 UTC

Iegādes, apvienošanās, pārņemšana

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

2026. g. 16. marts 20:51 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

2026. g. 16. marts 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 16. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Energy & Utilities Roundup: Market Talk

2026. g. 16. marts 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 16. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 16. marts 19:53 UTC

Galvenie ziņu notikumi

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

2026. g. 16. marts 19:43 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 16. marts 19:43 UTC

Tirgus saruna

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

2026. g. 16. marts 19:37 UTC

Tirgus saruna

Galvenie ziņu notikumi

Natural Gas Follows Oil Prices Lower -- Market Talk

2026. g. 16. marts 19:20 UTC

Galvenie ziņu notikumi

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

2026. g. 16. marts 19:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

2026. g. 16. marts 19:00 UTC

Tirgus saruna

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

2026. g. 16. marts 18:23 UTC

Tirgus saruna

LME Restarts Trading After Outage -- Market Talk

2026. g. 16. marts 17:36 UTC

Galvenie ziņu notikumi

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

2026. g. 16. marts 17:19 UTC

Tirgus saruna

Grains Sink as Investors Steer Toward Equities -- Market Talk

2026. g. 16. marts 17:14 UTC

Galvenie ziņu notikumi

Trump Ends News Conference

Salīdzinājums

Cenas izmaiņa

Mirati Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

-0.05% uz leju

Prognoze 12 mēnešiem

Vidējais 58.67 USD -0.05%

Augstākais 59 USD

Zemākais 58 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Mirati Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Mirati Therapeutics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

150 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

EBITDA

Pamatdarbības peļņa

Par Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.